Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.

Journal of controlled release : official journal of the Controlled Release Society - 1 Feb 2020

Kim Min Ju, Lee So Jin, Ryu Ju Hee, Kim Sun Hwa, Kwon Ick Chan, Roberts Thomas M

Abstract excerpt

The phosphoinositide 3-kinase (PI3K) and RAS signaling pathways are frequently co-activated and altered during oncogenesis. Owing to their regulatory cross-talk, the early attempts of targeting only one pathway have mostly ended up promoting the development of drug resistance. Here, we propose using small interfering RNA (siRNA) therapeutics to directly target the undruggable KRAS (siKRAS) in combination with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Silencing

Share to Mutation

Share to Ovarian Neoplasms

Share to Phosphatidylinositol 3-Kinase

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 31838203
DOI: 10.1016/j.jconrel.2019.12.019
PMCID: PMC7056267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment.PMID 31838203Read ↗

Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.Semantic proximity Read ↗

Targeting PI3K Signaling in Combination Cancer Therapy.Semantic proximity Read ↗

Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.Semantic proximity Read ↗

RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues.Semantic proximity Read ↗

Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.Semantic proximity Read ↗

Targeted Molecular Therapy of the PI3K PathwaySemantic proximity Read ↗

Development of siRNA payloads to target KRAS-mutant cancer.Semantic proximity Read ↗

Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth.Semantic proximity Read ↗

Statin-dye conjugates for selective targeting of KRAS mutant cancer cells.Semantic proximity Read ↗

Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.Semantic proximity Read ↗

MicroRNA-21 inhibitor (miR-21i) and Simvastatin-loaded poly (D,L-lactide-co-glycolide)/polyethylenimine (PLGA/PEI) nanoparticles for synergistic anticancer effect in Gastric CancersSemantic proximity Read ↗

MicroRNA-21 inhibitor (miR-21i) and Simvastatin-loaded poly (D,L-lactide-co-glycolide)/polyethylenimine (PLGA/PEI) nanoparticles for synergistic anticancer effect in Gastric CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.